-
Foreword Insights from Professor Ling Zhiqiang: Can these markers guide gastric cancer diagnosis and treatment?
Time of Update: 2022-01-09
lncRNA MT1JP inhibits gastric cancer cell proliferation, migration, invasion, and promotes apoptosis, which can be used as a potential therapeutic target and prognostic marker for gastric cancer .
-
[Nature Sub-Journal] A "high-risk, high-return" study-scientists transform CAR-T cells into cancer drugs "micro weapons"
Time of Update: 2022-01-09
To overcome these problems, a new type of CAR-T cell was developed, which is designed to express enzymes that activate systemically administered small molecule prodrugs in situ at the tumor site .
-
Bleeding and thrombosis associated with CAR-T therapy
Time of Update: 2022-01-09
Comment This article introduces a relatively unknown toxicity of CAR-T therapy and identifies patients who need close follow-up, especially those with baseline thrombocytopenia or higher grade ICANS .
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
-
Explore the headline sword refers to the "king of cancer"!
Time of Update: 2022-01-09
Recently, the team of Professor Yin Yuxin of Peking University School of Basic Medicine and collaborators of the Chinese Academy of Sciences and the Chinese People’s Liberation Army General Hospital applied machine learning combined with lipidomics and multi-omics techniques to comprehensively analyze the metabolic characteristics of pancreatic ductal adenocarcinoma (pancreatic cancer), and developed an artificial The intelligent-assisted PDAC serum metabolism detection method achieved 86.
-
When the greasy "Meta" meets the pure "Shengxin", what kind of sparks will it spark?
Time of Update: 2022-01-09
Prognostic analysis showed that the RFS of colon cancer patients in the chemotherapy group could be significantly differentiated in these cohorts by CRLSig (Figure 3A-3C) .
In addition to OS and RFS, CRLSig is also significantly related to the TNM staging of colon cancer patients undergoing chemotherapy (Figure 6B) .
-
Experts comment on Cancer Cell Fan Jia/Zhou Hu/Gao Daming/Gao Qiang to draw the multi-omics molecular feature panorama of intrahepatic cholangiocarcinoma
Time of Update: 2022-01-09
On December 30, 2021, Fan Jia, Academician of Zhongshan Hospital Affiliated to Fudan University, Researcher Zhou Hu from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Researcher Gao Daming from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, and Professor Gao Qiang's research group from Zhongshan Hospital Affiliated to Fudan University collaborated in Cancer A research paper titled Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma was published on Cell.
-
Nature Summary: Highlights and Setbacks of Oncology Drugs in 2021
Time of Update: 2022-01-09
It was approved by the FDA based on a single-arm, open-label, phase i/ii trial that included patients with locally advanced or metastatic NSCLC with KRASG12C mutations .
-
【News】Lolatinib for the treatment of ROS1-positive advanced NSCLC clinical trial approved in China
Time of Update: 2022-01-09
CStone Pharmaceuticals announced on January 4 that the clinical trial application (IND) of loratinib for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration (NMPA) of China .
-
Courier CStone's potential "best-in-class" ROR1 antibody conjugate drug is approved by the US FDA to enter the clinic
Time of Update: 2022-01-09
▎This article is transferred from the official WeChat account of CStone Pharmaceuticals (Suzhou, China, January 3, 2022) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs The leading biopharmaceutical company today announced that its CS5001 clinical trial application (IND) has been approved by the U.
-
"Logic gate" AAV gene therapy, let cancer cells "nowhere to escape" Medical Maihei Technology
Time of Update: 2022-01-09
Recently, a team of scientists from the Swiss Federal Institute of Technology Zurich has developed a logic-gated AAV gene therapy, which is used in combination with Roche's antiviral drug Cytovene (ganciclovir) in a mouse model of hepatocellular carcinoma It shows the potential of precisely targeting cancer cells, and can kill cancer cells more effectively while preserving healthy tissues, significantly reducing the tumor burden of hepatocellular carcinoma mice .
-
"Blood test for cancer" female version of Jobs convicted, is liquid biopsy reliable? NEJM review
Time of Update: 2022-01-09
In addition, compared with needle aspiration biopsy of a single tumor lesion, cfDNA analysis can better detect the molecular heterogeneity of multiple different clonal populations in a patient's tumor .
-
Express develops tumor microenvironment to activate innovative immunotherapy, cutting-edge exploration of new strategies for solid tumor treatment
Time of Update: 2022-01-09
"Reference: [1] Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics.
Retrieved January 3, 2021, from https:// en/Amberstone-Biosciences-Secures-12-Million-Series-A-Financing-to-Advance-Immuno-Oncology-Pipeline-of-Tumor-Microenvironment-Activated-Therapeutics Disclaimer: WuXi AppTec's content team focuses on introducing global biomedicine Health research progress .
-
[Collection] PD-1/PD-L1 drugs (NMPA/FDA) approved indications
Time of Update: 2022-01-08
Tumor immunotherapy does not directly attack cancer cells, but fights tumors by activating the body's own immune system, which has good safety and tolerance .
PD-1/L1 antibody drugs, as a representative drug for tumor immunotherapy, have achieved great success in the treatment of malignant tumors .
-
Selection of gastric cancer organoid models
Time of Update: 2022-01-08
Cell lines, animal models, and patient-derived tumor xenograft models all lack the characteristics that characterize the occurrence and development of gastric cancer, which limits the research on the pathogenesis of gastric cancer and the development of therapeutic drugs.
-
The Lancet Magazine's new year's heavyweight: 300,000 15-year data revealed!
Time of Update: 2022-01-08
Throughout the study, the hospitalization rates for blood vessels, non-diabetic-related cancers, and amputations were higher in men than in women (Table 2) .
Throughout the study, the hospitalization rates for blood vessels, non-diabetic-related cancers, and amputations were higher in men than in women (Table 2) .
-
Science Advances: DNA nanotubes break through the blood-brain barrier and bring hope to glioblastoma
Time of Update: 2022-01-08
Science Advances ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survivalThe research team used DNA nanotechnology to construct a single-stranded DNA nanotubes (ssDNA nanotubes), which can be used as a drug delivery system to cross the blood-brain barrier and target glioblastoma to improve the treatment effect and survival rate .
-
European Radiology: The value of deep convolutional neural networks in predicting preoperative microvascular infiltration and clinical prognosis of HCC patients
Time of Update: 2022-01-08
According to clinical radiology factors, DCNN probability and all factors, radiology (R), DCNN and combined nomograms were constructed in the training cohort (n = 892) ; the performance of each model was in the validation cohort (n = 244) Was confirmed .
-
The article is retracted due to imperfect informed consent: Paraneoplastic IgA vasculitis in elderly patients with lung metastatic adenocarcinoma
Time of Update: 2022-01-08
The authors want to apologize for their mistakes because they think verbal consent is sufficientThis article has been retracted at the request of the submitting author, Khashayar Farzam, as the University of Iowa Hospitals & Clinics patient consent procedure was not properly followed by the authors when preparing this manuscript.
-
Chest: Modified pathological T staging of NSCLC with visceral pleural infiltration (VPI): analysis of 1055 cases of NSCLC with swelling ≤3cm
Time of Update: 2022-01-08
Visceral pleural infiltration (VPI) is considered to be a poor prognostic factor for patients with non-small cell lung cancer ( NSCLC ) .
Visceral pleural infiltration (VPI) is considered to be a poor prognostic factor for patients with non-small cell lung cancer ( NSCLC ) .
-
Express AbbVie's ADC therapy is recognized by the FDA as a breakthrough therapy for the treatment of non-small cell lung cancer
Time of Update: 2022-01-08
It is used to treat patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild-type non-squamous non-small cell lung cancer (NSCLC) who have disease progression and c-Met overexpression during or after platinum drug treatment .
